Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital ACN Newswire

Innovation is the Key Benchmark, Focus on Four Healthcare Industry Sub-Sectors in 2023, Says Jafar Wang of Legend Capital

HONG KONG, Feb 15, 2023 - (ACN Newswire via SEAPRWire.com) - Legend Capital invested in 29 healthcare companies that officially disclosed financing rounds in 2022, according to the VBDATA Database. Since 2007, Legend Capital has continuously invested in healthcare across industry sub-sectors including innovative drugs, biotechnology, medical devices, diagnostic technology, professional services and supply chain. Overtime, it has built a powerful healthcare ecosystem encompassing more than 140 portfolio companies. Through value-added initiatives including strategic management and business empowerment activities, Legend Capital has the capability to bring far more value to the table in addition to financial resources.Breakthrough and global innovations are the key benchmarks by which Legend Capital judges and selects projects in a changing external environment. How did Legend Capital navigate the challenges of 2022 and how does it see the market in 2023? What are the key healthcare investment themes? In an interview with VCBeat, Jafar Wang, Co-Chief Investment Officer of Legend Capital, shared his perspectives:"Five significant changes in primary market investments"Legend Capital observed several important evolvements in the healthcare investment market during 2022:First, the industry's overall investment pace slowed down, with considerable decrease in deal count, deal size, and the speed of decision-making. Activity level of the healthcare investment market has returned to normalcy after an overheated period of 2020-2021, which now appears on the same level as 2019. Second, there has been significant changes in investors' selection criteria. Institutional investors need to evaluate whether a project has demonstrated breakthrough innovation, whether it is among the top three in its field, and whether it has the potential to compete on the global stage for first-in-class or best-in-class status. As a result, investors look to sector leaders for investment opportunities.Third, there is growing emphasis on exit and exit management.Fourth, emerging markets are receiving more attention as industry participants turn their overseas focus from developed markets to emerging economies. On the one hand, investors have increased their allocation to emerging markets, such as Legend Capital's expansion into Southeast Asia. Similarly, more players are aggressively expanding abroad in the hope that their products and services will reach the wider emerging markets. For Chinese healthcare companies, these markets will be a key destination in the next five to ten years.Lastly, there is general awareness in the industry that the window for biotech companies to transition into biopharma has closed for the moment. Biotech companies should continue to focus on their core competencies in technology innovation and product development, while actively pursue collaborations in manufacturing, supply chain, and downstream commercialization with top-tier industry players."An investment strategy focused on innovation and early-stage opportunities" Regardless of changes to the external environment, Legend Capital continues to uphold the importance of being an investor in value, innovation, in early-stage firms, in core technologies, and taking the long view. Our selection criteria for deals remain consistently high.In 2022, Legend Capital established a Frontier Biotechnology Fund to invest in innovative seed and start-up stage biotechnology and MedTech companies. Although such investments carry higher risks, they could potentially create game-changing results for the industry. This fund will mainly focus on the commercialization of ideas and products from academia, overseas returnees, and well-known spin-off teams or founders. Legend Capital values cutting-edge, innovative, and disruptive technologies, and we are willing to make bigger bets and dedicate more resources towards these seed and angel stage projects.Legend Capital is also devoted to investing in the independence and security of the healthcare supply chain. Two years ago, we put forward the view that an independent and secure supply chain, as well as import substitution, are among the best investment opportunities over the next five years. We are not only focused on the China market, but with an eye to the international potential of investee companies. The idea of supply chain investment is to help resolve bottlenecks faced by the industry while also serving the global market.In terms of Legend Capital's healthcare ecosystem, we are continuously expanding this ecosystem and improving synergies within. In the past, our value-added services were geared towards management guidance, but two years ago, we increased efforts to empower our portfolio companies with industry perspectives. To date, Legend Capital has invested in more than 140 healthcare companies, and established a complete, one-stop value-added service system across research, production, supply chain, and commercialization function. Our presence in sub-sectors from life science tools to preclinical research, clinical CRO, manufacturing and commercialization allow Legend Capital to bring synergy to portfolio companies. As this value-add ecosystem evolve and portfolio companies reap the benefits, oftentimes prospective investees become more receptive to our investment; they see Legend Capital as an investor with abundant industry resources, rather than a pure financial investor.Additionally, Legend Capital cooperates closely with industry-leading firms to bring additional resources to our healthcare ecosystem, which helps portfolio companies in their business development. Through product licensing and strategic collaborations, we have strengthened the connection among the ecosystem, portfolio companies, and industry peers. Working with healthcare companies in the industry not only aids the development of our portfolio companies, but also present potential new opportunities for Legend Capital. For instance, we have been able to generate new investments with our industry partners through efforts such as co-investments, incubation, and spin-offs. This may very well become a common investment practice in the future.Throughout 2022, Legend Capital had five healthcare-related IPOs, including Recbio Technology, R&G Pharmastudies, MicuRx Pharmaceutical, Sipai Health Technology, and Lunit; in addition, nearly 10 portfolio companies were exited through M&A. A RMB 300+ million GP-led secondary transaction was completed during the year after concluding a $270 million one in 2021. We will continue to utilize secondary tools in the future to generate large-scale exits for existing LPs, which also create opportunities to partner with new LPs while supporting our portfolio companies on their journeys, to ultimately achieve a win-win for all parties."Opportunities are bred from innovation" Legend Capital maintains a diversified portfolio of companies in innovative drugs and biotechnology, medical devices and diagnostic technology, professional service and supply chain, and will continue to actively invest going forward. In 2023, our healthcare investment efforts will focus on three main areas.For biotech, Legend Capital will concentrate on small nucleic acid medicines and CGT-related verticals such as gene editing and induced pluripotent stem cells. In MedTech, more focus will be placed on life science tools, import substitution, and consumer healthcare. In professional services and supply chain, with the evolvement of CGT and small nucleic acid pharmaceuticals, CRO and CDMO may present new investment prospects. In addition to investing in pharmaceutical CRO and CDMO, Legend Capital saw success in 2022 with investments in medical device and diagnostic CRO and CDMO so we will continue to invest in these fields.Leveraging our vast portfolio ecosystem, Legend Capital will continue to make significant investments in supply chain independence, including upstream consumables, machinery, and life science tools. To achieve the best outcomes, Legend Capital will collaborate with its leading portfolio companies in the future on co-investments and help them with potential M&A opportunities.In summary, Legend Capital believes that the best investment opportunities arise from breakthrough innovation. For instance, our portfolio company Harbour BioMed recently announced that the U.S. FDA has cleared the IND application to commence clinical trials of its globally first-in-class fully human monoclonal antibody HBM1020 targeting B7H7 (also known as HHLA2) in the U.S. HBM1020 is also the globally first-ever monoclonal antibody targeting B7H7 cleared by the regulatory agency for clinical trials. HBM1020 may present a novel anti-tumor therapeutic complementary to PD-(L)1 therapeutics to patients, especially for PD-L1 negative/refractory patients. Regardless of the outcome, we believe a company will stand a better chance to break out from intense competition when it has the courage and boldness to be the innovator.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Portfolio Company Bespin Global Completes USD100m Series D Financing ACN Newswire

Legend Capital Portfolio Company Bespin Global Completes USD100m Series D Financing

HONG KONG, Dec 15, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Capital Portfolio Company Bespin Global, a Korea-headquartered cloud services company, has recently completed its Series D round financing of USD100 million, which will be used mostly for acquisitions.Concurrent with the investment, the investor, e& Enterprise, a leading digital services provider in UAE (formerly Etisalat Digital), and Bespin Global will form a joint venture that will serve customers in the Middle East, North Africa and Pakistan.John HanJoo Lee, CEO and co-founder of Bespin Global said, "By combining forces with e& enterprise in the METAP region, we are bringing much needed cloud managed services to the region where cloud adoption is about to explode. e& enterprise has deep customer relationships and the trust of its customers and Bespin Global has the deep cloud management capabilities. Together, we can accelerate cloud adoption in the region. Additionally, we welcome e& as our shareholder. It's a clear validation of our track record as a trusted cloud managed services provider on the global stage."Bespin Global helps its customers in their digital transformation by providing cloud migration, cloud management and related SaaS offerings. It is the first multi-cloud managed service provider in East Asia with partnerships with Amazon Web Services, Microsoft Azure, Google Cloud, Aliyun, Tencent Cloud, and Naver Cloud.The company has offices in 9 countries including Korea, China, Japan, Singapore, Vietnam, Indonesia, the US, UAE, and Saudi Arabia. It has over 1,700 customers which range from large enterprises to fast growing startups.Legend Capital led Bespin Global's Series A financing in 2017, and continued to invest in the company's Series B financing in 2019. As an early investor, Legend Capital has provided support and help to Bespin Global in global cooperation, enterprise management and subsequent financing, to promote Bespin Global's development.In 2020, Legend Capital introduced Serverworks, a leading AWS Cloud integrator in Japan, to Bespin Global. The two companies established a joint venture in September 2021, entering the Japanese market officially.John HanJoo Lee, CEO and co-founder of Bespin Global said, "It was Legend Capital that first introduced us to the UAE investors that led to the successful funding round with e&. Many venture capital firms talk about adding value, but only a few actually do. Legend Capital continues to add value beyond just capital. We are so lucky to have such a great partner as our investor."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing ACN Newswire

Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing

HONG KONG, Dec 9, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital. The proceeds will be mainly used for the capacity expansion of core pipeline products 5-hydroxymethylfurfural (HMF), 2,5-furandicarboxylic acid (FDCA) and 2,5-tetrahydrofuran dimethanol (THFDM), and the continuous development of downstream derivatives.Founded in 2021 with the vision of "Biomass Change Lives", GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain. The members of its founding team graduated from the Dalian Institute of Chemical Physics, Chinese Academy of Sciences, and have nearly 20 years of research foundation and industrialization experience in the fields of biomass catalytic conversion and furan-based material design and development. At present, the R&D team building has also been completed from biomass, derivatives to polymers, which ensures the cutting-edge of the company's product development and the availability of end products.According to Dr. John Zhang, CEO of GS Biotech, the company has taken the development model of promoting the "two-wheel drive" of the dual track as an important strategic direction. On the one hand, the company has completely solved the problems of HMF cost and raw material sources; its original HMF continuous production process, which completed the verification of multi-dimensional cost reduction measures, has greatly reduced the production cost and effectively improved the efficiency, and it is expected that the production cost of HMF will be controlled within RMB10,000 per ton in the future three years from the extraction of non-grain raw material sources to the iterative path of the production process and to the planning of expanding production capacity. Meanwhile, the company has also reserved more than 20 kinds of high-value-added monomers and is simultaneously promoting the verification of the application of each monomer in the terminal market. Moreover, GS Biotech established a joint venture, Xinshengtai Materials, with an AI-powered drug R&D unicorn company XtalPi Inc to focus on using AI technology to accelerate the reverse design of derivatives and improve the development efficiency of downstream derivatives to further accelerate its high-efficiency and accurate market development process.On the other hand, the company has also made significant progress in the design, R&D and industrialization of degradable new materials. The new biodegradable plastic PEOX, another important pipeline of the company, has completed the 150L pilot scale experiment and obtained market terminal verification. The performance indicators of PEOX can be compared with PGA and the price of the terminal product will be approximately RMB10,000/ton after the large-scale production. With the special performance of the product and the support of policies, many leading enterprises in the industry are negotiating with the company to sign an underwriting agreement to apply PEOX in the field of disposable packagings such as agricultural mulch, plastic bags, straws, and lunch boxes.Legend Capital said: "Under the background of China's strategy in carbon peaking and carbon neutrality and the pursuit of sustainable energy development, petroleum-based chemical materials will gradually be replaced by bio-based materials, which are produced from sustainable resources. HMF is an important bio-based platform compound with great potential for downstream derivatives. GS Biotech has pioneered the HMF continuous production process globally and realized the large-scale and low-cost production of HMF. It has opened the entire industry chain from upstream core monomers to terminal applications and innovatively introduced AI and high-throughput machine synthesis technology into the development of downstream derivative products. The core team of GS Biotech graduated from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences. With nearly 20 years of research foundation and industrialization experience in the field of biomass catalytic conversion, GS Biotech has shown strong capabilities in continuous R&D, production management, and resource integration. Legend Capital has long focused on technology investments linked to carbon peaking and carbon neutrality, and we look forward to working with GS Biotech to promote technological change in the field of bio-based materials."As an interdisciplinary subject of information science, life science and material science, synthetic biology and bio-based materials have always been the direction that Legend Capital has paid close attention to in the field of carbon-neutral technology investment. Legend Capital's investments in the carbon-neutral field focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power, and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others; in the field of synthetic biology and bio-based materials, Legend Capital has invested in many outstanding companies such as Giant Biogene (02367.HK), GS Biotech, Huili Biotech, and Tidetron Bioworks Technology.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq ACN Newswire

Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq

HONG KONG, Nov 13, 2022 - (ACN Newswire via SEAPRWire.com) - On the evening of November 11, Beijing time, Legend Capital portfolio company Atour Lifestyle Holdings Limited ("Atour") was officially listed on the Nasdaq Stock Exchange in the United States. It has priced its initial public offering of 4,750,000 American Depositary Shares ("ADSs") at US$11.0 per ADS.Founded in 2013, Atour is a leading hospitality and lifestyle company in China with a distinct portfolio of lifestyle hotel brands, such as A.T. HOUSE, Atour S, ZHOTEL, Atour Hotel, Atour X and Atour Light, as well as scenario-based retail brands, including Atour Market. It has further divided its private labels into three product lines - aTOUR PLANET, SAVHE and Z2GO&CO. As of June 30, 2022, Atour has launched a total of 1,967 SKUs, 62.8% of which are private-label products. According to the prospectus, as of September 30, 2022, Atour has opened 880 hotels, a year-on-year increase of 26%. According to Frost & Sullivan, Atour is the largest upper midscale hotel chain with a diversified brand portfolio in China in terms of room numbers for five consecutive years as of the end of 2021. As an important institutional investor and close partner of Atour, Legend Capital led the investment in Atour in 2016, and continued to make additional investments in Atour's subsequent financing rounds in 2017 and 2021. Following the investment, Legend Capital has continuously supported Atour's development by providing multiple value-added services in terms of development strategy, corporate governance and incentive mechanism, listing work and business resources.Legend Capital said: " The past nine years have witnessed Atour's continuous development since its first hotel opening in 2013. Looking back at the development of China's hotel industry over the past decade, Atour is the only company with precise positioning and bringing changes to China's hotel industry. It has brought a new service standard to the industry. It is also a lifestyle consumer brand providing a warm and happy feeling that can be remembered by customers. Atour's founder and the team are rare talents in the domestic hotel industry. The team is dynamic and young, with over ten years of operating experience in the hotel industry. The listing marks a new milestone for Atour. It is not only an affirmation of the past achievements of Atour, but also an acknowledgment of their tenacity and professionalism. This also reflects the expectation for the future innovation and development of Atour. As Atour's investor, we are proud to be able to participate in and witness its growth."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea.It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX ACN Newswire

Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX

HONG KONG, Nov 7, 2022 - (ACN Newswire via SEAPRWire.com) - On November 4, 2022, Legend Capital portfolio company Giant Biogene (2367.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. The number of Giant Biogene's offer shares under the global offering is 22,608,800 shares at an issue price of HK$24.3 per share, which includes 2,261,200 Hong Kong offering shares, 20,347,600 international offering shares, as well as a 15% over-allotment option.Giant Biogene is a leader in the bioactive ingredient-based professional skin treatment product industry in China and the first company in the world to successfully develop and industrialize recombinant collagen skin treatment products. Giant Biogene has been the largest collagen-based professional skin treatment product company by retail sales in China for the latest three consecutive years since 2019. According to Frost & Sullivan, Giant Biogene was the second-largest professional skin treatment product company in China in 2021, and its Collgene and Comfy, the flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively. Giant Biogene is the first company to obtain a medical device registration for recombinant collagen-based products in China.Legend Capital participated in Giant Biogene's only round of financing in 2021. Following the investment, Legend Capital provided Giant Biogene value-added services on core issues such as business strategy discussion, upstream and downstream business resource docking, executive talent introduction, and IPO listing process.Richard LI, President of Legend Capital, said: "Congratulations to Giant Biogene on its successful listing on the main board of the Hong Kong Stock Exchange. Legend Capital is very honored to be an investor in Giant Biogene and to carry out in-depth investment cooperation with the company. With 22 years of development and unremitting efforts under the leadership of the company's management, Giant Biogene has achieved excellent results and has become a pioneer enterprise in the field of biosynthetic materials and products in China. We hope that Giant Biogene will make steady progress and achieve greater achievements in the future development and continue to brave the wind and the waves in the changing market."Tony WANG, Managing Director of Legend Capital, said: "Giant Biogene is a pioneer in the synthetic biology industry. It not only builds a leading technology platform for genetic engineering, tissue engineering and material engineering but also applies scientific research results to the field of healthcare. Giant Biogene demonstrated the best practice out of the combination of production, education and research. We look forward to this diligent and pragmatic team continuing to go forward and leading Chinese brands to the international market in the future." About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round ACN Newswire

Led by Legend Capital, ClinBrain Completes Nearly CNY200 million Series C Round

HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Recently, the healthcare big data leader ClinBrain completed the Series C round of financing of nearly CNY200 million, led by Legend Capital. This round of financing will facilitate ClinBrain to continuously deepen its expertise in the field of healthcare big data, explore the deep integration of big data and AI in the healthcare industry, promote the R&D of underlying technologies and scenario-based applications, and accelerate the promotion of industrial digital and intelligent upgrading.As a high-tech enterprise focusing on the healthcare big data intelligence platform, digitalized and intelligent application services, ClinBrain was shortlisted as the SDRI (specialized, refined, differential and innovative) "little giant" enterprise by the Ministry of Industry and Information Technology this year.At the beginning of its establishment in 2013, ClinBrain realized that healthcare, as a data-intensive and knowledge-intensive industry, is inseparable from the support of data, no matter in clinical services, operations management or medical research. ClinBrain has been committed to the direction of data governance and intelligent application of hospitals. By leveraging years of its industry experience and technical capabilities, the company has made breakthroughs in many fields, such as collecting data from hospital business systems without an interface, effectively identifying the data structure of complex business systems, effectively cleaning the business data of different versions and different manufacturers, forming effective and practical data quality rules to improve the data quality of hospitals, and conducting structured processing of unstructured data such as medical records and pathology. Moreover, with its powerful natural language processing (NLP) capabilities and robust rule and knowledge base, including more than 3900 data cleaning and quality rules embedded and tens of millions of medical concept term relationships accumulated, ClinBrain is also capable of automatically identifying the data structure of each version of more than 500 business manufacturers and realizing high-quality data cleaning and structured processing of unstructured data.LIU Huanchun, Chairman of ClinBrain, said, "Under the complex and volatile economic background and the ongoing pandemic situation, the recognition by many investors has reflected the market position, technological level and value of ClinBrain. After this round of financing, ClinBrain will promote the company's development to a new level by making further efforts in scientific and technological innovation and talent introduction."Raymond CHEN, Co-chief Investment Officer of Legend Capital, said, "Healthcare big data is a key driver of the digital and intelligent transformation of the pharmaceutical industry, which is in line with the long-term megatrend of new healthcare infrastructure. As a leading healthcare big data enterprise in China, ClinBrain provides full-link solutions from data governance to medical scenario applications based on its rich industrial theoretical knowledge and practical experience. We are optimistic that ClinBrain will create a new development form in healthcare big data by continuously expanding more products and customer application scenarios."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round ACN Newswire

Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round

HONG KONG, Nov 1, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital. The fresh capital will be used for the R&D of Easy-Flow's peripheral intervention pipeline.Data shows that there are a large number of patients with peripheral vascular disease, of which about 40 million patients with lower extremity arteries and about 100 million patients with varicose veins. Given the number of patients is increasing yearly, there is a huge clinical demand foreseeable, indicating that the peripheral vascular interventional device trajectory is likely to be the next market worth CNY10 billion.Founded in November 2021, Easy-Flow is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices. The company develops products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases. Since its establishment, Easy-Flow has been committed to creating peripheral interventional product packages, and developing Me-too, Me-better and Me-only products at the same time. It is expected that several products will be submitted for registration or initiated into clinical practice by 2030.In addition to its independent R&D, Easy-Flow also simultaneously carries out external cooperation to further expand its product pipeline. Easy-Flow recently has reached a cooperation with Control Medical in the United States to introduce the FDA-approved Control(TM) mechanical thrombus removal system, which can be manually controlled by doctors to achieve efficient and controllable thrombus aspiration.The founder of Easy-Flow, MIAO Zhenghua, who has more than 20 years of experience in the field of vascular intervention, said: "At present, the biggest challenge to many startups is how to rapidly commercialize their certified products. On the one hand, many founders have R&D backgrounds but lack experience in marketing their products quickly, and some companies only focus on one or two items, making them hard to cover marketing expenses with their revenue and profits. On the other hand, there are many product categories in the field of peripheral interventional devices. The treatment of disease often requires multiple products, and it is difficult to support the market with a single product. Therefore, the integrated package of peripheral interventional products is more suitable for commercial promotion."Regarding this financing round, Joe ZHOU, managing director of Legend Capital, said: " Legend Capital has long focused on investment in medical devices. We have invested in a number of companies focusing on the unmet clinical needs of major diseases, especially chronic diseases. Cardiovascular and cerebrovascular-related fields have always been the focus of systematic analysis and research of the Legend Capital team. Easy-Flow has a talent team with extensive experience, led by the founder MIAO Zhenghua. We are very pleased to cooperate with Easy-Flow and participate in the development of the company. In the future, Legend Capital will give full play to the advantages of the healthcare portfolio ecosystem to support Easy-Flow's development and move forward hand in hand."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round ACN Newswire

Co-Led by Legend Capital, Top Gene Delivery Enterprise VectorBuilder Secures CNY410mn in Series C Round

HONG KONG, Oct 20, 2022 - (ACN Newswire via SEAPRWire.com) - VectorBuilder Biotechnology (Guangzhou) Co., Ltd. (hereinafter referred to as "VectorBuilder"), a top gene delivery enterprise, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. The proceeds will facilitate VectorBuilder in continuously promoting the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines. VectorBuilder was founded by Dr. Bruce Lahn, a world-renowned molecular biologist who was a tenured professor at the University of Chicago and a researcher at Howard Hughes Medical Institute (HHMI). The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine. VectorBuilder has provided more than 1.2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies worldwide, and its gene-drug CRO and CDMO projects are spread all over North America, Europe, Japan and South Korea.Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder, said: "I'd like to take this opportunity to extend my sincere gratitude to investors for the support and trust. Due to a robust technical accumulation and an excellent business model in the gene delivery industry, VectorBuilder enjoys the highest market share in the global gene carrier scientific research market, and we jointly launched the construction of a 45,000-square-meter gene delivery R&D and production base with Guangzhou Development District Investment Group in April 2022. We hope to take this financing round as an opportunity to further accelerate the comprehensive upgrade and optimization of the technology platform and promote the expansion of production capacity and global presence. VectorBuilder has become a pioneer in the entire gene delivery industry chain by empowering basic scientific research and accelerating the clinical application of gene drugs. We believe VectorBuilder will enter thousands of life science laboratories worldwide and become a well-known brand in the field of life science. We will empower the gene-drug industry through core technologies and help China to "overtake" on the genetic drug track. At the same time, we hope to overcome genetic diseases, improve human health, and provide irreplaceable value to the industry and the world."Jeff Wang, Managing Director of Legend Capital, said: "VectorBuilder is the world's leading gene delivery company, providing full-chain solutions from basic scientific research to clinical application of gene delivery. It is an honor to participate in the future development of VectorBuilder. Dr. Bruce Lahn is an expert in the field of biotechnology innovation, and we are optimistic about VectorBuilder's comprehensive ecological service platform for gene delivery in life science and biomedicine. VectorBuilder has developed the world's first system providing online design, offline production carrier construction and downstream application service, serving thousands of top biopharmaceutical companies and research institutes. We believe VectorBuilder has a promising future as the genetic medicine industry develops." About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
GalaxySpace Completes a New Financing Round with Legend Capital Re-upped ACN Newswire

GalaxySpace Completes a New Financing Round with Legend Capital Re-upped

HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - GalaxySpace, a Chinese commercial aerospace company, recently completed its latest financing round with a post-investment valuation of approximately RMB11 billion. As an existing shareholder, Legend Capital continued to support the company by following up on this financing round.Legend Capital first invested in GalaxySpace in 2018 and continued to follow up on the company's subsequent financing rounds in 2019, 2020 and 2022, increasing its investment layout of cutting-edge technology and supporting the development of GalaxySpace.Founded in 2018, GalaxySpace is the first unicorn enterprise in the field of commercial aerospace and satellite internet in China. Xu Ming, founder, chairman and CEO of GalaxySpace, said: "This round of financing will be mainly used for the R&D of satellite Internet-related technologies and the development of commercial applications. GalaxySpace will accelerate the R&D of core technologies such as stackable flat panel satellites, flexible multi-beam phased array technology, flexible solar wings, digital processing payloads, etc., and also the construction of mass-producing low-cost satellites. Step by step, we will move forward to the 6G era of the Internet of Everything."Nowadays, global space infrastructure construction has been developing rapidly, and commercial aerospace is becoming one of the new driving forces of the world's economic development. According to a Morgan Stanley report, the global space economy is expected to be worth $1 trillion by 2040, and the satellite Internet is expected to account for 50% or even 70% of the market growth.At present, GalaxySpace's new-generation stackable flat-panel satellite has entered the prototype development stage, which is also the first flat-panel satellite in China and will be launched early next year. It is believed that the development of stackable flat-panel satellites will promote the mass production of satellites and the rapid deployment of large-scale constellations. In the future, GalaxySpace will seize the development opportunities and fully utilize the advantages of small wins and rapid iteration of commercial aerospace to make a continuous innovative contribution to China's satellite Internet construction.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Leadrive Technology Completes Series C Financing, Legend Capital Re-upped ACN Newswire

Leadrive Technology Completes Series C Financing, Legend Capital Re-upped

HONG KONG, Sep 25, 2022 - (ACN Newswire via SEAPRWire.com) - Leadrive Technology, a leading supplier of power semiconductor and motor control solutions for new energy vehicles, recently announced its completion of the series C financing. As the existing shareholder, Legend Capital continued to support this round of financing.This round of financing will be mainly used for the construction of the IGBT/SiC power module packaging production line, the operation of the rapid production of motor control products, and the R&D of the latest generation of silicon carbide power modules and motor control products.Founded in 2017, Leadrive Technology has been committed to the forward development and production of power semiconductor modules and high-performance motor control units, bringing high-quality electric power to global automotive enterprise customers and consumers. After five years of rapid development, Leadrive Technology is equipped with mature technology and product solutions in the power modules and motor control units. A variety of high-performance IGBT power modules and main-drive dual-motor controller products developed by Leadrive have been installed in several hybrid models of many OEMs, achieving mass shipments and fully entering the passenger car market. With many test indicators at the industry-leading level in vehicle testing, the silicon carbide motor controller independently developed by Leadrive has also been designated and recognized by many downstream customers in the global market. In the future, Leadrive will center on the two core electrification foundations of power semiconductor modules and motor control units, and continue to invest in advanced technology development, product platform iteration, capacity expansion, and other fields. By leveraging its technological advantages, Leadrive works with industry chain partners to empower the electrification trend of the automotive industry and make outstanding contributions to promoting the technological progress of the industry.Dr. Jie Shen, the CEO of Leadrive, said: "Currently, the company is in a critical stage of rapidly developing large-scale delivery. This round of financing will mainly be used for the construction and implementation of the company's power module packaging production line and the replenishment of working capital for multiple mass production projects. For the smooth delivery of this round of financing, I would like to thank all the new and existing shareholders for their trust and strong support. With pursuing excellence in our mind, we take it as our duty to promote the technological progress of the industry as well as to make a continuous innovative contribution to the development of the new energy vehicle industry in China." About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital: The Logic of Technology Investment Has Changed ACN Newswire

Legend Capital: The Logic of Technology Investment Has Changed

HONG KONG, Sep 2, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Capital recently announced that it made its 100th IPO following the listing of its AI medical portfolio company Lunit on the KOSDAQ market on 21 July 2022. In addition, Legend Capital's CRO portfolio company R&G Pharmastudies was successfully listed on the ChiNext of Shenzhen Stock Exchange on 2 August 2022, while on 5 August 2022, the innovative drug portfolio company MicuRx Pharmaceuticals went public on the STAR Market, becoming the 101st IPO and the 102nd IPO in Legend Capital's investment portfolio. In a recent interview, Richard Li, President of Legend Capital, revealed the history of Legend Capital in technology investment and proposed that the logic of technology investment has undergone important changes.Over 100 IPOs and 100 UnicornsLegend Capital pays more attention to the quality rather than the quantity of IPOs, but the 100th IPO remarks an important milestone for Legend Capital. Richard Li, President of Legend Capital, said in the interview: "What matters is not about the quantity of IPOs, but more about the repeated verification of the investment expertise of Legend Capital team, who has long been rooted in technology investment.From Lunit to R&G Pharmastudies and MicuRx Pharmaceuticals, these IPO achievements at home and abroad are in line with Legend Capital's development: starting from the USD fund and growing stronger with the RMB fund. Among its peers, Legend Capital stands out with its distinctive feature - it is well-versed in the system of USD funds, but is also rooted in China and inherently adept at a local investment with the RMB fund.Looking back at Legend Capital's development history, we can see a microcosm of the changes in China's technology investment. In Richard Li's memory, since the company's investment in iFLYTEK in 2001, Legend Capital has been systematically investing in companies that are in the early stages of technological innovation, and many of them have become industry leaders such as iFLYTEK, Spreadtrum, CATL, WuXi AppTec, Pharmaron, Wuxi Lead Intelligent and CNGR Advanced Material, etc., tapping into core sectors of new energy, semiconductor, life science, new materials and so on. So far, among Legend Capital's invested companies, there are over 100 unicorn companies with a valuation of over USD1 billion, creating a huge and systematic technology investment footprint.With over two decades of expertise, Legend Capital has cultivated a profound understanding of the technology and innovation drives of China, accumulated rich resources around industries, and built a powerful portfolio ecosystem. Legend Capital helps overseas enterprises expand business in the Chinese market and promotes the global expansion of enterprises by bridging key resources in China such as R&D and supply chain.On the other hand, by leveraging its "China Insights", Legend Capital also helps portfolio companies and entrepreneurs in China to "go global" and achieve strategic objectives across the border by integrating overseas resources and opportunities, helping portfolio companies to respond to complex changes in the global industry landscape and meanwhile generating new investment opportunities.The Significance of 100 IPOsLooking back at the 100 IPOs, they are remarkably diverse while at the same time representing a consistent theme. Regarding the breakdown of listing location, 31 of our portfolio companies were successfully listed on Shenzhen Stock Exchange, 20 on Shanghai Stock Exchange, 22 on Hong Kong Stock Exchange, 1 on Taiwan Stock Exchange, 4 on New York Stock Exchange, 16 on Nasdaq, 5 on Korea Stock Exchange, 1 on Japan Exchange Group. With the majority listed on A-share markets, Legend Capital has extensive exit experience in multiple capital markets, which is relatively rare in investment institutions in China.From the market value (in RMB), there is 1 company with a market value of trillions - CATL; 10 companies with a market value of 100 billion, such as iFLYTEK, Pharmaron, WuXi AppTec, WuXi Biologics, Wuxi Lead Intelligent, Shanghai Putailai New Energy, CNGR Advanced Material, and JD Logistics; 15 companies with a market value of more than 50 billion, and 43 companies with a market value of more than 10 billion; and 25 of them are "little giants" companies with Specialization, Refinement, Differentiation & Innovation features. Legend Capital is active behind the rise of many Chinese technology companies.Richard Li summarized several characteristics regarding Legend Capital's 100 IPOs: First, it covers multiple sectors. The second is balance, which is also one of the deep impressions that Legend Capital has left on the public - internationalization practices in RMB funds and extremely strong localization capabilities in USD funds. Third, investment in technological innovation projects is the main focus, and investment in pure business model-innovation projects is relatively small. In addition, Legend Capital acts as the lead investor in most of its portfolio with a relatively large shareholding ratio, thus having board seats and could exert a certain influence on the operation of portfolio companies.Patience capital in industrial chain investmentFounded in 2001, Legend Capital has experienced 20 years of technology iteration and innovation in China. "The founding team of Legend Capital all came from industrial rather than financial backgrounds, which determines the industrial and technology innovation genes of Legend Capital," Richard Li recalled. In China, Legend Capital is a pioneer in making technology investments using USD funds, much earlier than many of today's first-tier USD funds. Since 2015, Legend Capital has changed from a single fund investment business team to a unified platform to manage the operation of multiple funds, including long-term PE funds, TMT specialized funds, health care specialized funds, etc., to compose a more synergistic team.This synergy effect is reflected in Legend Capital's investment across different platforms and funds. With regard to its investment in the semiconductor industry, Legend Capital has systematic research on semiconductor companies and makes selective investments, with different funds investing in different types of targets. For example, Legend Capital invests in some enterprises that integrate resources and iterate products under a mature technology framework. Once successful, they will create a huge market of the replacement of the current framework, and even the first round of financing for these enterprises would reach billions of dollars. In the long run, they will grow into companies with a market value of hundreds of billions of dollars. Under such circumstances, Legend Capital will make a large proportion of investment through mature PE funds.However, the entire semiconductor industry is still in the early stage of development currently, and the latest semiconductor technology represents a new design concept and architecture, as well as a trend in cutting-edge technology. At this stage, many start-up technology companies need our support in the form of early-stage fund investment that accompanies their development in the long run. This will in turn contribute to the diversification, synergy and expansion of Legend Capital's investment tools and targets.The investment in the lithium battery industry, on the other hand, reflects the industry chain investment theme that is rooted in the industry background of the Legend Capital team. Benefiting from the long-term in-depth layout in the industrial mapping and the precise control of investment timing, Legend Capital has realized a number of landmark investments in the new energy field. Among them, projects such as Lead Intelligent, CATL, PUTAILAI, CNGR, Hymson have created huge returns for Legend Capital.Based on the prediction of the scale and trend of the downstream industry, Legend Capital has also systematically invested in assisted and autonomous driving along the direction of intelligent and unmanned new energy vehicles, as well as related sensor, radar, chip, and other projects in similar niches. Typical cases include Pony.ai, Zongmu Technology, MUNIU Tech, Black Sesame Technologies, etc.Richard Li said frankly: "Distinct from the internet sector, hard technology companies have a relatively long incubation period. Technology verification and productization need to be completed in the early stage, then put into the market, and then gradually scale up. The industry has large development potential and the enterprises have strong profitability. However, the market environment is complex, so it is hard for 'one winner to take all', and it is unrealistic to rely on first-mover advantage to achieve home runs. Therefore, investment institutions need to grasp the inflection point of the industry, such as when the effectiveness of the technology could be verified and when the product develops rapidly, which tests investors' judgment on timing.Richard Li summed it up in this way: To invest in science and technology, it is necessary to have an industrial mindset, sort out the industrial map, and then invest according to the timing of different stages and nodes of the industry. After that, we need to wait, and time will show us the answer. Investment institutions should have the patience and determination to accompany enterprises for a long time.The Logic of Technology Investment Has Changed Looking back on 20 years of experience in China's Venture Capital, Richard Li exclaimed that the industry is undergoing great changes today. "It's a systemic change including funding sources, investment directions and exit channels." He believes that these years are a critical turning point for the industry. Investment institutions need to make targeted adjustments to accommodate the new environment.In the past, the fundraising and exit of USD funds were both structured abroad, which led to most of the funds not actually investing in China. "To some extent, it is equivalent to going public in the United States with financial statements submitted from companies in China, and then selling shares in the United States market to exit." US dollar investors must now face up to the fact that the old game is over.Richard Li bluntly remarked that when USD funds began to shift investment focus from business model innovation to hard technology, in addition to the changes in target investment fields, the fundamental difference between the historic "two-end abroad" to invest in Chinese Concept Stocks and the new reality of China-rooted model of "investing onshore in China" put forth significant requirements for the localization of investment institutions, which requires long-term accumulation of resource networks and support from mid to back office.Besides, to be successful in using USD funds to invest in hard technologies in China with a focus on local listings and exits, it is very important to manage a complementary large-scale RMB fund as the cooperation between the two derives unique differentiation. Otherwise, we can only invest in individual "Cusp" projects opportunistically, rather than systematically investing in a long-term sustainable manner.This is also the challenge and opportunity that Legend Capital has always emphasized. Our latest plan focuses on technology investment, while paying attention to domestic A-share exit channels, we also take into account the exit channels for overseas investment projects in overseas capital markets, including Hong Kong stocks, US stocks, and capital markets such as South Korea and Japan. "Actually, these plans are things that we started doing a few years ago. If you just start to do these things today, I think it's too late." Said Richard Li.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative.For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Pursued progress while ensuring stability and built up momentum, Legend Holdings realized revenue of RMB237,685 million in the first half of 2022

HONG KONG, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Holdings Corporation (stock code: 3396.HK) announced today the unaudited condensed consolidated interim results for the six months ended June 30, 2022 (the "Reporting Period"). During the Reporting Period, the Company's revenue was RMB237,685 million and the net profit attributable to equity holders of the Company amounted to RMB2,131 million.Mr. Li Peng, Executive Director and CEO of Legend Holdings, said that in the face of the complex international environment, in the first half of 2022, Legend Holdings pursued progress while ensuring stability, and deepened the strategic thinking of "industrial operation, technological innovation", made steady improvement in its corporate competitiveness and operational efficiency, and further strengthened its investment and layout in the field of science and technology innovation; At the same time, we gave full play to the role of "chain leader", practiced the concept of green development, actively fulfilled corporate social responsibility, and devoted ourselves to contribute to the high-quality development of China's economy.During the Reporting Period, Legend Holdings further consolidated the foundation of its industrial operations and strengthened its operational management. The revenue of the segment increased by 4% year-on-year to RMB235,775 million, and the net profit attributable to the equity holders of Legend Holdings increased by 20% year-on-year to RMB2,830 million. -- Lenovo achieved revenue and profit growth for the ninth consecutive quarter. While maintaining its position as the world's No.1 PC maker, Lenovo accelerated the development of new growth drivers with the revenue share of the non-PC business reaching a new high of 37% in the second quarter-- Levima Group took the lead in achieving import substitution in the field of EVA photovoltaic materials. In the first quarter, the upgrading and transformation of EVA devices realized the expected effect, and the result in the second quarter reached a new high. In addition, the company continued to focus on the field of new materials, advancing the new projects in an orderly manner, and entered the field of electronic specialty gas; -- The core business of Joyvio Group develops well as a whole. Joy Wing Mau continued to improve its vertically integrated fruit supply chain and achieved rapid growth in revenue. Global demand and prices for seafood products continued to rebound, and the revenue and profit of Joyvio Food have been improved; -- With a healthy core capital adequacy ratio and strong international credit ratings, Banque Internationale a Luxembourg S.A. ("BIL") achieved solid growth - successfully navigating the challenges faced by Europe's economy. Meanwhile, BIL obtained QFLP status in Shenzhen, through which it will further support the introduction of foreign capital into China's market and other initiatives.During the Reporting Period, the industrial incubations and investments segment delivered stable and sound growth despite capital market volatility.-- Legend Capital raised funds of RMB3.5 billion, invested in 26 new projects, and 4 portfolio companies went public; -- Legend Star invested in nearly 20 new projects, more than 40 enterprises under management completed their next funding round, and it exited approximately 10 projects. The first round closing of the firm's fifth USD fund and the final closing of its artificial intelligence special fund were also completed.; -- Fullhan Microelectronics's market share has significantly increased, and its performance has achieved growth. It continued to invest in mid- and high-end surveillance products to enhance profitability, and the expediting growth of smart home & smart automotive products has served as new driving engines;-- Lakala maintained China's No. 2 operator in terms of bank card transaction volume and leading operator in QR code payments. At the same time, it proactively provided technological support for other businesses; -- The production and operation of Eastern Air Logistics have recovered steadily and achieved steady improvement in performance; -- Zhengqi Holdings focused on the field of scientific and technological innovation, carried out industrial exploration and investment layout, and has so far helped 11 of its portfolio companies in total successfully go public; -- JC Finance & Leasing achieved solid performance and year-on-year revenue growth amid the pandemic.Increasing investment in scientific and technological innovation, adhering to innovation-driven development and continuously supporting the growth of Specialized and Innovative EnterprisesLegend Holdings stays true to its original aspiration of "revitalizing the country through business". It has further increased its investment in technological innovation in line with the national strategy of achieving high-quality development driven by technological innovation and has achieved promising results. -- Steady implementation of the "plan of doubling investments in Research and Development"In the first half of 2022, Legend Holdings' Family Group's total R&D investment (excluding the capitalized R&D spending) reached RMB7.212 billion, and currently owns over 20,000 granted patents, ranking top among Chinese enterprises in various patent awards. Lenovo remains committed to its plan of doubling investments in R&D; it increased R&D spending by 23% year-on-year and grew R&D headcount by 29% year-on-year. Levima Advanced Materials adhered to its innovation-driven strategy. During the Reporting Period, it completed the laboratory R&D development for 9 new products and processes, the production technology formulas for 15 new products, and the industrialization of 5 new products. -- Continuously "long-sought" in the field of science and technology In the first half of 2022, Legend Holdings' family group invested in nearly 50 new technology companies, covering multiple fields such as cutting-edge technologies, hard & core technologies, healthcare and medicine, and has contributed to the development of specialized and innovative enterprises in China through its empowerment. During the year as of August 15, 2022, 12 of its portfolio companies have successfully completed IPOs. Close to 50 of Legend Holdings' family group's portfolio companies made the newly announced list of the fourth official list of state-level specialized and innovative enterprises, such as Noitom, Hua Kong Tsingjiao, Spacety, Union Semiconductor, EasyDiagnosis Biomedicine, NuVolta Technologies, etc. Up to now, Legend Holdings' family group has nearly 100 specialized and innovative companies in its portfolio.Adhering to green growth, playing the full strength as a chain leader, and actively fulfilling corporate social responsibilityLegend Holdings is committed to promoting green development philosophy through the efforts of its portfolio companies to seize the green development opportunities, and jointly build an ecological civilization. Lenovo has set a goal of net-zero carbon emissions by 2050, transforming into "net-zero carbon emission plants" on the basis of its state-level green plants. The Company continues to create and provide smart solutions that facilitate the green transformation, empowering over 300 top industrial enterprises in China. Levima Advanced Materials focused on the development of new energy materials and biodegradable materials on top of its existing EVA photovoltaic film business; BIL helped Chinese companies issue overseas green bonds to facilitate the development of green finance; at the same time, Legend Capital, Legend Star, Zhengqi Holdings, etc. have further expanded investments in related fields to promote innovation and technological progress.In terms of industrial chain, Legend Holdings promoted its subsidiaries to give full play to their advantages in operations and supply chains and assisted the coordinated development across the industrial chains. Lenovo was named a Gartner Global 25 Supply Chain for the eighth consecutive time. 90% of its manufacturing was from China, with 2,000 level-1 suppliers, directly providing more than 350,000 jobs. Levima Advanced Materials continued to make efforts in the field of new materials, expanding vertically to the upstream of the industrial chain while horizontally expanding to new segments, driving the mutual development with SMEs.Corporate social responsibility is an important part of Legend Holdings' overall strategy. The Company actively responds to the national call to steadily promote the implementation of the national employment stabilization policy within the family group, and carefully formulated and closely tracked various recruitment plans. While extensively attracting social talents, it focused on the recruitment of fresh graduates from colleges and universities, and actively expanded the scale of recruitment. In terms of public welfare undertakings, Legend Holdings has long focused on key areas such as fostering start-ups, contributing to rural revitalization, promoting social integrity and responding to disasters for years and insists on investing and carrying out relevant work effectively.Mr. Ning Min, Chairman and Executive Director of Legend Holdings, said that, under the strong leadership of the Communist Party of China's Central Committee, China coped well with the changes in the international environment, and achieved economic and social development while effectively coordinating pandemic prevention and control, adhering to the guiding ideology of "people-centered", and achieved a series of results in various tasks, which also created a good environment for the development of enterprises. In the first half of 2022, the Company continued to improve its position, strengthen its capabilities, seize the important opportunities arising from the transformation and upgrading of Chinese enterprises, focus on the real economy, increase efforts in the field of scientific and technological innovation, and earnestly fulfill its corporate social responsibilities. In the future, we will continue to aim at accomplishing the great goal of building a world-class enterprise, and contribute to the journey of achieving high-quality development and common prosperity! Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY ACN Newswire

Led by Legend Capital, Multi-omics-leading Enterprise APTBIO Closes Series B with Hundreds of Millions of CNY

HONG KONG, Aug 19, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Applied Protein Technology Co., Ltd. ("APTBIO"), a leading enterprise focused on mass spectrometry-based multi-omics applied to precision medicine, recently announced the completion of its Series B with hundreds of millions of CNY, which is led by Legend Capital. The proceeds from this round of financing will be used to accelerate the product R&D, market expansion, and data-driven precision medicine development and help APTBIO continue to develop in mass spectrometry multi-omics applications, innovative drug development, and preclinical research, making a forward-looking layout for the construction of precision medicine services driven by big data and AI. Founded in July 2004, APTBIO is one of the earliest biotechnology companies engaged in proteomics technical services and biopharmaceutical research and analysis services in China and participated in establishing China's biological mass spectrometry applications from scratch. With headquarter in Shanghai, APTBIO has a nationwide sales network and it has built innovative technology centers, data centers, and clinical testing centers in Shanghai, Yiwu, and Taizhou, with a total area of more than 20,000 square meters. Centering on the construction of the life and health industry chain, APTBIO has established four major technology platforms through technical cooperation and its innovation capabilities: a large-scale multi-omics platform, biopharmaceutical preclinical research and small-scale production platform, mass spectrometry clinical detection and companion diagnostic platform, and an AI and big data platform. By laying out the three business segments of technology services, biomedical CRO services, and mass spectrometry clinical testing services, APTBIO has built a business map around multi-omics and big data to provide a precise platform for the perfect transformation from basic research to clinical application. Ms. CHEN Wei, the founder of APTBIO, said: "I would like to take this opportunity to extend my sincere gratitude to our investors. This round of capital input fully validates the rapid development and future potential of APTBIO in mass spectrometry multi-omics-based precision medicine and pre-clinical CRO for drug R&D. With the completion of the new round of financing, we will further promote the local and global market layout, innovative biomedical business interaction, and data-driven precision medicine capacity, to contribute to the human health industry."Hank ZHOU, the co-chief investment officer of Legend Capital, said: "APTBIO is a leading enterprise in multi-omics R&D services in China, covering a wide range of areas such as technology services, biomedical R&D, precision medicine, and it provides integrated services for the transformation from basic research to clinical application. APTBIO has laid out cutting-edge technologies in various fields in advance, such as proteomics and metabolomics, and its high-quality R&D technical team has achieved breakthroughs in multiple research fields. We are honored to participate in the future development of APTBIO and are willing to work together with the company to establish APTBIO as a leader in the multi-omics R&D industry."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully ACN Newswire

Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully

HONG KONG, Aug 15, 2022 - (ACN Newswire via SEAPRWire.com) - On August 2, 2022, R&G Pharmastudies Co., Ltd. (stock code: 301333.SZ), a China-leading CRO enterprise invested by Legend Capital, was successfully listed on the ChiNext of Shenzhen Stock Exchange. R&G Pharmastudies publicly issued 15,000,000 shares at a price of RMB78.88 per share, and the total amount of funds raised is expected to be RMB1.18 billion.R&G PharmaStudies is a large-scale professional clinical trial outsourcing service supplier in China. It has established a complete set of pharmaceutical R&D outsourcing service systems covering the whole chain of clinical trials. R&G PharmaStudies provides integrated services throughout the entire process of clinical trials with its comprehensive drug R&D service system; the main services offered by the company cover clinical trial operation services, clinical trial site management services, biological sample testing services, data management, and statistical analysis services, clinical trial consulting services, clinical pharmacology services, etc. R&G PharmaStudies is committed to providing high-quality and efficient clinical research services in line with international standards. With a broad and high-quality customer base, it has provided professional services for about 750 Chinese and foreign pharmaceutical companies.Legend Capital invested in the Series A round of R&G PharmaStudies in the second half of 2017 and has kept on supporting the development of R&G PharmaStudies. Jafar Wang, the Co-Chief Investment Officer of Legend Capital, said, "Congratulations on the successful listing of R&G PharmaStudies! R&G PharmaStudies is a veteran of China's pharmaceutical clinical CRO industry and has long provided full-chain clinical CRO services for Chinese and foreign innovative pharmaceutical enterprises. The successful listing will be the starting point of the new long run of R&G PharmaStudies; with its global vision, well-known expert team, and high-quality service system, we are optimistic about the long-term development potential of R&G PharmaStudies, and look forward to the continuous growth of the company." Legend Capital has a systematic layout in CRO/CDMO. In addition to R&G PharmaStudies, Legend Capital has invested in plenty of other new-drug R&D CRO/CDMO companies, such as WuXi Apptec, WuXi Biologics, Pharmaron, Bellen, ClinChoice, SAFE Pharmaceutical, dMed Biopharmaceutical, XiHua Scientific, BirdoTech, Intellective Biologics, Biortus, and Simoon Record.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully ACN Newswire

Legend Capital Super Antibiotic Portfolio Company: Scarce Enterprise MicuRx Pharmaceuticals is Listed on the STAR Market Successfully

HONG KONG, Aug 9, 2022 - (ACN Newswire via SEAPRWire.com) - On August 5, 2022, Legend Capital portfolio company MicuRx Pharmaceuticals, a scarce enterprise in super antibiotic, was successfully listed on the STAR Market. MicuRx Pharmaceuticals issued 130,000,000 shares this time, accounting for 19.84% of the total share capital after the issuance. The total amount of funds raised is expected to be about RMB 960 million at the issue price of 8.16 yuan per share. MicuRx Pharmaceuticals is an innovative drug company focusing on novel therapeutics for infectious diseases. With global independent intellectual property and competitiveness, MicuRx Pharmaceuticals is committed to the discovery, development, and commercialization of innovative drugs for unmet medical needs. The main products from MicuRx Pharmaceuticals include Contezolid, MRX-4, and MRX-8. Since the company's establishment, MicuRx Pharmaceuticals has adhered to the principle of "Better therapy through superior medicine", focusing on the increasingly severe problem of bacterial resistance worldwide. With the core competitiveness of solving clinical problems and differentiated innovation, MicuRx Pharmaceuticals aims to provide more effective and safer therapeutic options for patients suffering from the most common and severe drug-resistant bacterial infections. MicuRx Pharmaceuticals has an international core R&D team and has established R&D centers in China and the US. The company's R&D team has rich experience in international innovative drug development and management, and it has led or participated in developing a number of marketed anti-infective new drugs. Legend Capital invested in MicuRx Pharmaceuticals in 2020 and has long supported the company's development. "Congratulations to MicuRx Pharmaceuticals. The successful listing represents the recognition of MicuRx Pharmaceuticals' innovative R&D in the field of multi-drug-resistant bacterial infection and its globally competitive innovative drug. Legend Capital and the MicuRx team have established a deep friendship, and Legend Capital is honored to participate in the MicuRx business led by Dr. Zhengyu YUAN, the founder of MicuRx Pharmaceuticals. Dr. YUAN is a very tenacious and spiritual entrepreneur who dares to take risks, filling the Chinese market gap in the scarce field of multi-drug-resistant bacterial infection. With the consolidation of the company's leading edge and position, Dr. YUAN has not only built an international team and an innovative global enterprise but also made positive contributions to the development of human health." Said Legend Capital.Legend Capital has long paid close attention to investment in significant themes in the field of life sciences. In addition to MicuRx Pharmaceutical, Legend Capital has also made investments in plenty of other outstanding companies, many of which were listed on A-shares and H-shares, such as Pharmaron (300759.SZ) (03759.HK), Kingmed Diagnostics (603882.SH), Wuxi Apptec (603259.SH) (02359.HK), WuXi Biologics (02269.HK), Recbio (02179.HK), Innovent Biologics (01801.HK), Berry Genomics (000710.SZ), Harbour BioMed (02142.HK), New Horizon Health (06606.HK), and Chemclin Diagnostics (688468.SH).About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital (https://www.linkedin.com/company/legend-capital). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
New Power to Legend Capital Carbon Neutral Investment Portfolio: Ruicycle Raises Over RMB 300 Million from Series B ACN Newswire

New Power to Legend Capital Carbon Neutral Investment Portfolio: Ruicycle Raises Over RMB 300 Million from Series B

HONG KONG, Aug 8, 2022 - (ACN Newswire via SEAPRWire.com) - Shenzhen Ruicycle Environmental Protection Technology Co., Ltd (also known as Hengchuang Ruineng), a battery recycling company, recently accomplished the B round of fundraising with over RMB 300 million, which is backed by Legend Capital. This round of fundraising will be mainly used to improve the development of the echelon utilized product series, the construction of new energy retired lithium battery recycling capacity, and the expansion of new lithium battery wet recycling technology.Founded in 2017, Ruicycle is a national high-tech enterprise dedicated to "Making New Energy a Truly Green Energy", deeply engaging in the field of recycling and comprehensive utilization of retired power batteries. It is committed to pursuing the concept of green and low-carbon development. Directing at the end of the new energy industry, Ruicycle has built an industrial ecological closed loop of large-scale automatic safe crushing, zero-pollution treatment, and high-efficiency recycling of lithium batteries based on the core technologies of lithium battery echelon utilization, material regeneration, and new material regeneration. Meanwhile, centering on the national carbon peaking and carbon neutrality policies, Ruicycle has achieved the traceability of carbon footprint and the quantification of carbon reduction, continuously making contributions to low-carbon development for the new energy industrial chain.In 2020, Ruicycle was granted the qualifications of "Echelon Utilization White List" and "Recycling Utilization White List", becoming the fully licensed enterprise in the lithium battery recycling industry. Ruicycles revenue exceeded RMB 1 billion with a CAGR of over 100% in 2021. Now it has been recognized as the first echelon enterprise in China's power battery recycling and comprehensive utilization industry.Ruicycle is the world-first company devoting intelligent management of temperature-sensing cameras to the retired battery storage field. It has established industrial bases for echelon utilization and recycling in Huizhou, Jiangmen, and Ganzhou, respectively, achieving a recycling capacity of 150,000 tons per year of retired power batteries. At the same time, Ruicycle has also been cooperating with Legend Capital's portfolio company Milkyway, a leading dangerous chemicals logistics enterprise, to build a global leading ESG recycling system.CHEN Zhipeng, the founder of Ruicycle, said: "We are a relatively young team. In keeping with the trend of the new energy era, we are eager to learn more from industry predecessors to root in the physical manufacturing industry more deeply. At the same time, we look forward to having more aspiring youngsters join us to create an efficient organization and together make contributions to the globalization of new energy industrialization experience.Legend Capital's investments in the carbon-neutral field focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power, and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others.Legend Capital has long been optimistic about investment opportunities in the new energy vehicle industry chain and has invested in a number of automation equipment, lithium batteries, and materials companies, many of which went public successfully, such as Wuxi Lead Intelligent Equipment (300450.SZ), CNGR Advanced Material (300919.SZ), Shanghai Putailai New Energy Technology (603659.SH), Shenzhen Hymson Laser Intelligent Equipments (688559.SH), Shenzhen Colibri Technologies (002957.SZ). At the same time, Legend Capital is also one of the early investors of CATL (300750.SZ).About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Led by Legend Capital, The Leading Intelligent Special Robot Company AKA Robotics Completes Series A Financing ACN Newswire

Led by Legend Capital, The Leading Intelligent Special Robot Company AKA Robotics Completes Series A Financing

HONG KONG, Jul 28, 2022 - (ACN Newswire via SEAPRWire.com) - Shenzhen AKA Robotics Technology Co., LTD. (hereinafter referred to as "AKA Robotics"), a leading intelligent special robot company, recently completed its Series A financing round, which was led by Legend Capital. This round of funds will be used to invest in R&D and accelerate its market expansion of the special robotic series products and its overseas market layout, with the mission of "cleaning the world, safe operation".AKA Robotics was established in 2017 and has grown into an enterprise that provides intelligent special robots and comprehensive green solutions for rust removal, cleaning, spraying, polishing, and the inspection of large steel-structure facades. Its robot products have been widely used in ships, petrochemicals, wind power, and other industries.The founding team of AKA Robotics was formed by experts in the field of robotics, coming from Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. The founder of AKA Robotics is a key technical talent of the Chinese Academy of Sciences, the chief scientist of key R&D projects of the Ministry of Science and Technology, a doctoral supervisor, and a professor-level senior engineer with profound experience in technology R&D and operation management. AKA Robotics has obtained nearly 100 patents and software copyrights in the fields of core technologies, including wall-climbing robots, intelligent control algorithms, controllers, ultrahigh pressure water jet technology, and machine vision.Raymond CHEN, Co-Chief Investment Officer of Legend Capital, said: " Legend Capital continues to pay attention to the investment opportunities in the field of robots. At present, the application of special robots in ships, petrochemicals, wind power, and other industries is facing an inflection point. With the ability to reduce manual work in harsh environments, the robots will play a greater role in industrial production and social life with broad market space. The AKA Robotics team is modest and pragmatic and has been concentrating on polishing products for many years. AKA Robotics has taken the lead in forming large-scale applications in ships and is a leading enterprise in special robots. Legend Capital is very honored to lead this round of financing, and we look forward to AKA Robotics making more breakthroughs in technology, products, and commercialization in the future. At the same time, Legend Capital will continue to support AKA Robotics in growing into a global and platform-based special robot company by providing more proactive value-added services."About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service, and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
GameFi on Fire: Dragon Crypto Gaming’s Dragon Crypto Argenti Token ($DCAR) and The Legend of Aurum Draconis SeaPRwire

GameFi on Fire: Dragon Crypto Gaming’s Dragon Crypto Argenti Token ($DCAR) and The Legend of Aurum Draconis

Sydney, Australia, July 22, 2022 – (SEAPRWire) – Dragon Crypto Gaming (DCG) initial dex offering (IDO) of Dragon Crypto Argenti ($DCAR), a utility token for its expanding GameFi ecosystem, will be open for registration on July 20th, 2022, with the IDO taking place on July 26th, 2022. DCG has partnered with Avalaunch, the leading platform for decentralized fundraising on Avalanche. Following the token release, The Legend of Aurum Draconis, an action-adventure role playing game (RPG), will go live on the Avalanche C-chain blockchain soon after. Founded by a team of experienced and passionate software developers and gamers, Dragon Crypto Gaming is building an evolving digital universe that combines engaging gameplay with play-and-earn mechanics, user ownership and sustainable economics. DCG’s game offerings are established on a dual token economy featuring two native tokens: Dragon Crypto Aurum ($DCAU) and $DCAR. Both tokens have major utility in all DCG game offerings. From the outset, $DCAR will drive the economics of crafting and land-ownership in The Legend of Aurum Draconis. Players can also stake $DCAR to earn a share of platform revenues. Future utility includes being the native gas token for DCG’s future Avalanche subnet. The Legend of Aurum Draconis is, at its core, an old-school fantasy RPG. The game combines the best from traditional off-chain gaming with the economic incentives made possible through decentralized finance (DeFi). No expense was spared in developing a full-fledged RPG experience, with an exciting, story-driven questline, strategic turn-based battling, resource gathering, crafting, character skills development and customization. Through the game’s token economy, players will share in the economic benefits of the game in the form of NFT items and token rewards. Players will be able to craft, equip, repair, buy and sell thousands of unique NFT items through the in-game marketplace. “As gamers at heart, our team’s main goal is to offer a fun and fulfilling gaming experience on the blockchain. DCG pushes the boundaries of play-and-earn gaming by leveraging the global reach and limitless potential of decentralized finance and truly enjoyable gameplay” – Daniel Zandberg, Head of Creative Content. To celebrate the launch of $DCAR and The Legend of Aurum Draconis, readers of this article may enter the competition for a chance to win a Dragon Crypto Hero NFT by visiting the following link: https://gleam.io/pl8iX/10-dcg-heroes-giveaway ABOUT DRAGON CRYPTO GAMING Founded in August 2021, Dragon Crypto Gaming is at the forefront of blockchain gaming and is committed to building a GameFi ecosystem that combines the best of off-chain gaming with blockchain decentralization. The team launched a highly successful NFT collection – Tiny Dragons – that was minted and sold out within minutes of launch. This was soon followed with Tiny Dragons Arena a casual player-vs-player mini-game based on the same theme, with over a thousand on-chain matches having taken place as of July 2022, Dragon Crypto Gaming is backed by some of the most reputable Avalanche ecosystem participants, including the Blizzard Avalanche Ecosystem Fund, Muhabbit Capital, Aventures DAO and Keychain Capital. Social Links: Twitter: https://twitter.com/DCGgamefi Discord: https://discord.gg/DragonCryptoGaming Youtube: https://www.youtube.com/channel/UCKgqX0wKK8Fpa9aEgQ6USbQ/featured Media Contact Company: Dragon Crypto Gaming Contact: Dan, Head of Creative Content Email: dan@dragoncryptogaming.network Website: https://dragoncrypto.io/ SOURCE: Dragon Crypto Gaming The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully ACN Newswire

Legend Capital Portfolio Company: The Global-Leading AI Medical Imaging Company Lunit Goes Public Successfully

HONG KONG, Jul 21, 2022 - (ACN Newswire via SEAPRWire.com) - On July 21st, 2022, Lunit, a leading global AI-based cancer solutions provider invested by Legend Capital, was successfully listed on the KOSDAQ market. Founded in 2013, Lunit successfully established itself as the world's top-notch artificial intelligence technology solution provider, mainly focusing on developing medical software to assist physicians in the realm of tumor diagnosis and treatment. Lunit's flagship products are Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT is an AI-powered image screening solution, that detects and classifies chest abnormalities and breast cancer. Lunit SCOPE is an AI biomarker for immunotherapy, providing therapy response information that can critically affect treatment outcomes for cancer patients. Legend Capital led Lunit's series B investment round in June 2018 and continued to support Lunit's global business expansion via three additional follow-on investments in 2019 and 2021. For the past 4 years, Lunit not only has produced world-leading AI medical solutions but also gained its commercial value achieving rapid topline growth. Lunit's annual revenue grew by over 460% in 2021 since its initial product commercialization in 2019. As of now, Lunit's image diagnostic products have been certified by 42 countries/regions, including FDA, CE, and KFDA. The company will keep expanding into the global market through cooperation with international giants like GE Healthcare, Fujifilm, and Philips, etc. Legend Capital will continue to assist Lunit in finding untapped business opportunities in China by building up branding and introducing rich portfolio resources for cooperation. Brandon Suh, CEO of Lunit, said: "Lunit's target market for cancer detection and diagnosis is worth 110 billion US dollars (of which the United States accounts for ~USD 45bn and the rest USD 65bn). Lunit's AI medical image analysis technology has significant advantages over traditional technology, and our accurate and efficient solutions have been appreciated by global medical institutions. Lunit's ongoing global expansion can be attributed to the support from our existing partners, Legend Capital has been one of Lunit's key partners in helping us grow our China business by introducing reliable local partners. Legend Capital has been and will continue to be Lunit's strategic global partner going forward." "We like to invest in companies that have a global vision, world-leading technology, and global expansion capabilities. We were very impressed with Lunit's ambition to go global at our initial investment," said Joon-Sung Park, Managing Director of Legend Capital. "With the world's top-notch AI medical imaging technology, Lunit INSIGHT can significantly improve abnormalities detection and early-diagnosis rate, remarkably enhancing the efficiency of cancer diagnosis and treatment. Lunit has built a professional team with technology experts and medical professionals. The six co-founders are all graduates of the Korea Advanced Institute of Science and Technology (KAIST), the nation's first public, research-oriented science and engineering institution. With a commitment to empowering the medical industry by AI technology, Lunit has also hired 12 full-time doctors with an in-depth understanding of medical service. It has provided AI healthcare services to approximately 600 medical institutions in over 40 countries, and has signed an exclusive business contract with Guardant Health, the world's largest liquid biopsy diagnostic company, to collaborate on cancer drug development." At present, "Lunit INSIGHT CXR Triage" and "Lunit INSIGHT MMG" have been certified by the U.S. Food and Drug Administration (FDA) by the end of 2021, and Lunit will continue to expand the global market by obtaining Medical Device Single Audit Program (MDSAP) certification in the US, Canada, Japan, Australia and Brazil, etc. Legend Capital has invested heavily in companies that integrate technology and the medical industry and has kept betting on AI medical sectors. In addition to Lunit, Legend Capital has also invested in AI medical companies such as Xbiome, an AI microbiome drug development company; StoneWise, an AI drug R&D platform; Deepwise, an AI medical imaging company; BioMap, a biocomputing platform; Deep Informatics ++, an AI medical pathology diagnosis company; and Unimed, an AI brain diagnosis and treatment platform.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB ACN Newswire

Co-led by Legend Capital, Huili Biotechnology Completes Series A Financing Round with Hundreds of Million RMB

HONG KONG, Jul 7, 2022 - (ACN Newswire via SEAPRWire.com) - Jiangsu Huili Biotechnology Co., Ltd ("Huili Bio"), a next-generation synthetic biology enzyme computational design platform, recently announced the completion of its Series A financing round with hundreds of million RMB. This financing round was co-led by Legend Capital and the fresh capital will be used to accelerate the construction and operation of large-scale production facilities, the R&D of new product pipelines and the expansion of the talent team.Founded in 2018, Huili Bio is dedicated to the computational design of enzyme components at the core of synthetic biological reactions. With cutting-edge achievements, Huili Bio is one of the few bio-manufacturing companies with comprehensive capabilities in core technology, mass production on a large scale and closed-loop commercialization. It provides solutions in multiple fields such as pharmaceutical intermediates, animal protection and food. In addition to an R&D center in Tianjin, Huili Bio has also established a production base in Taizhou City, Jiangsu Province, which is under the expansion of flexible production line. Huili Bio's enzyme computational design platform is the first computational platform in China to realize the full-scenario design of enzymes. This platform enables the company to transform products in the pharmaceutical field, so as to achieve high efficiency from laboratory development, industrial production to commercialization, reducing costs by nearly 30% and increasing yields by almost 70% compared to traditional chemical methods, and also helps Huili Bio deploy more than 10 innovative products in various fields.Commenting on the financing, Henry JI, Executive Director of Legend Capital, said: "The synthetic biomaterials market is vast and an important area in the green and low-carbon direction. As the core component of synthetic biology, the design and transformation of enzymes will benefit more traditional biotechnology industries with low-cost and sustainable green production methods. Legend Capital has long focused on investment in the 'IT+' industry, and Huili Bio is a model of combining information technology and biotechnology (IT+BT). With a background in combining industry and research, Huili Bio is a company with differentiated product selection and multi-pipeline extension capabilities. The company has mastered the industry's leading enzyme computing design technology and has rapidly achieved the scale production of high-value-added products such as pharmaceutical intermediates through the layout of the whole industry chain and has been fully recognized by the industry's head customers. Legend Capital is glad to join hands with Huili Biotech to contribute to China's biological 'intelligence'."As an intersection of information science, life science and material science, synthetic biology and bio-based materials have been the focus of Legend Capital's carbon-neutral technology investments. Under the background of carbon peaking and carbon neutrality, Legend Capital's investments focus on energy decarbonization, vehicle electrification/intelligence, synthetic biology, etc. Energy decarbonization includes photovoltaic, wind power and smart grid; vehicle electrification/intelligence includes lithium battery vehicles, hydrogen fuel cell vehicles, battery recycling and others. Legend Capital has made investments in the field of synthetic biology by investing in outstanding companies such as Huili Bio, Zhongke Guosheng, and Tidetron Bio.About Legend CapitalFounded in 2001, Legend Capital is a leading VC&PE investor focusing on the early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, South Korea. It currently manages USD and RMB funds of over US$10 billion in commitments, and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies by solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit www.legendcapital.com.cn/index_en.aspx and follow us on LinkedIn @Legend Capital ( https://www.linkedin.com/company/legend-capital ). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More